共 247 条
- [1] Cosentino F(2020)2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD Eur. Heart J. 41 255-323
- [2] Grant PJ(2021)Safety of semaglutide Front. Endocrinol. 12 645563-791
- [3] Aboyans V(2019)Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes Clin. Pharmacokinet. 58 781-515
- [4] Bailey CJ(2021)The PRISMA 2020 statement: an updated guideline for reporting systematic reviews BMJ 372 n71-1844
- [5] Ceriello A(2009)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement BMJ 339 b2535-984
- [6] Delgado V(2011)The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials BMJ 343 d5928-851
- [7] Smits MM(2021)Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes N. Engl. J. Med. 385 503-1480
- [8] Van Raalte DH(2016)Semaglutide and cardiovascular outcomes in patients with type 2 diabetes N. Engl. J. Med. 375 1834-286
- [9] Granhall C(2021)Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Lancet 397 971-109
- [10] Donsmark M(2019)Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes N. Engl. J. Med. 381 841-50